EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Protection From Demyelination by the Novel Adenosine Dual A 2A / A 2B Receptor Antagonist P626 in EAE and Cultured Oligodendrocyte Precursor Cells

M Morozzi, F Cherchi, C Sasia, L Frulloni, G Videtta, M Venturini, D Catarzi, F Varano, S Calenda, C Ceni, G Vagnoni, V Colotta und 3 weitere

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von M Morozzi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence,…. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Oligodendrocyte Precursor Cells, Receptor, Adenosine A2A, Adenosine A2 Receptor Antagonists. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NextGenerationEU and Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), Ente Cassa di Risparmio di Firenze, Fondazione Italiana Sclerosi Multipla.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic inflammatory disease characterised by myelin and axonal loss. Lack of remyelination is primarily attributed to the failure of oligodendrocyte progenitor cells (OPCs) to differentiate into mature oligodendrocytes. The neuromodulator adenosine can influence OPC differentiation, and by selectively stimulating A 2A and A 2B receptors (A 2A R, A 2B R), it inhibits OPC maturation. In the efforts of developing remyelinating and neuroprotective agents, this study evaluated the ability of a novel dual A 2A R/A 2B R antagonist, P626, in the experimental autoimmune encephalomyelitis (EAE) mouse model and cultured OPCs. EAE mice, 14 days after MOG 35–55 immunisation, received intranasal administration of P626 for 2 weeks, which improved motor symptoms, as evidenced by reduced clinical scores and enhanced performance on the rotarod test, and alleviated thermal and mechanical hypersensitivity without significantly affecting body weight. In spinal cord sections, P626 protected from the reduction of Luxol Fast Blue staining and increased myelin basic protein staining in immunohistochemical analysis. Patch‐clamp experiments on cultured OPCs exposed to high extracellular adenosine concentrations demonstrated that P626 prevented the A 2A R‐ and A 2B R‐mediated reduction in sustained I K and transient I A currents, both essential for cell differentiation. In conclusion, P626 showed efficacy in reducing neurological symptoms and demyelination in an MS model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalomyelitis, Autoimmune, ExperimentalOligodendrocyte Precursor CellsReceptor, Adenosine A2AAdenosine A2 Receptor AntagonistsDemyelinating DiseasesReceptor, Adenosine A2BAnimalsMiceCells, CulturedCell DifferentiationSpinal CordMice, Inbred C57BLFemaleMyelin SheathOligodendroglia

Stichwörter der Autor:innen

adenosine receptorsautoimmune experimental encephalomyelitisdemyelinationmultiple sclerosisoligodendrocyte progenitor cellspain

Substanzen

Receptor, Adenosine A2AAdenosine A2 Receptor AntagonistsReceptor, Adenosine A2B

Autor:innen und Institutionen

  • Section of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Florence, Italy.
  • Section of Pharmaceutical and Nutraceutical Sciences, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Sesto Fiorentino, Italy.

ORCID-Profile: N Galeotti

Förderung

  • NextGenerationEU and Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP)
  • Ente Cassa di Risparmio di Firenze
  • Fondazione Italiana Sclerosi Multipla
  • Ministero dell'Università e della Ricerca

Zitieren

APA

Morozzi, M., Cherchi, F., Sasia, C., Frulloni, L., Videtta, G., Venturini, M., Catarzi, D., Varano, F., Calenda, S., Ceni, C., Vagnoni, G., Colotta, V., Coppi, E., Pugliese, A. M., & Galeotti, N. (2025). Protection From Demyelination by the Novel Adenosine Dual A 2A / A 2B Receptor Antagonist P626 in EAE and Cultured Oligodendrocyte Precursor Cells. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70952

Vancouver

Morozzi M, Cherchi F, Sasia C, Frulloni L, Videtta G, Venturini M, et al. Protection From Demyelination by the Novel Adenosine Dual A 2A / A 2B Receptor Antagonist P626 in EAE and Cultured Oligodendrocyte Precursor Cells. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70952

BibTeX
@article{Morozzi2025,
  author = {Morozzi, M and Cherchi, F and Sasia, C and Frulloni, L and Videtta, G and Venturini, M and Catarzi, D and Varano, F and Calenda, S and Ceni, C and Vagnoni, G and Colotta, V and Coppi, E and Pugliese, A M and Galeotti, N},
  title = {Protection From Demyelination by the Novel Adenosine Dual A 2A / A 2B Receptor Antagonist P626 in EAE and Cultured Oligodendrocyte Precursor Cells},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70952}
}
Kostenlos starten →